Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Cristina Nieto-Jiménez"'
Autor:
Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Adrián Sanvicente, Jorge Bartolomé, Cristina Nieto-Jiménez, Alberto Ocana
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Therapeutic strategies targeting non-adaptive immune cells are currently in clinical development. γδT cells are a small subtype of T cells (1-10% of total T cells) that mediate their effector function without the necessity of the antigen presenting
Externí odkaz:
https://doaj.org/article/7d774cf911074c7781f4b84be65f5c1a
Autor:
Alfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, Cristina Nieto-Jiménez, Lucía Paniagua-Herranz, Adrián Sanvicente, Emiliano Calvo, Pedro Pérez-Segura, Víctor Moreno, Francisco Moris, Alberto Ocana
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA),
Externí odkaz:
https://doaj.org/article/c72087b5dfa54ed0aa029fccbd8b25e2
Autor:
Adrián Sanvicente García, Manuel Pedregal, Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Pedro Pérez Segura, Gyöngyi Munkácsy, Balázs Győrffy, Emiliano Calvo, Víctor Moreno, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 10, p 5345 (2024)
The identification of targets that are expressed on the cell membrane is a main goal in cancer research. The Lymphocyte Antigen 6 Family Member G6D (LY6G6D) gene codes for a protein that is mainly present on the surface of colorectal cancer (CRC) cel
Externí odkaz:
https://doaj.org/article/12a3623042cd4919b4effc47d41c292d
Autor:
Adrián Sanvicente, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Lucia Paniagua-Herranz, Igor López Cade, Győrffy Balázs, Víctor Moreno, Pedro Pérez-Segura, Emiliano Calvo, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3987 (2024)
Immuno-oncology has gained momentum with the approval of antibodies with clinical activities in different indications. Unfortunately, for anti-PD (L)1 agents in monotherapy, only half of the treated population achieves a clinical response. For other
Externí odkaz:
https://doaj.org/article/6cdddf10de4345e7aa95611bb8650b3a
Autor:
Cristina Nieto‐Jiménez, Adrián Sanvicente, Cristina Díaz‐Tejeiro, Víctor Moreno, Alfonso lopez deSá, Emiliano Calvo, Joaquín Martínez‐López, Pedro Pérez‐Segura, Alberto Ocaña
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Introduction Antibody‐drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications. Material and methods In this article, we performed a deep analysis of their clinical landscape
Externí odkaz:
https://doaj.org/article/445511a833964204a594eaf0a23f9c5e
Autor:
Esther Cabañas Morafraile, Cristina Saiz-Ladera, Cristina Nieto-Jiménez, Balázs Győrffy, Adam Nagy, Guillermo Velasco, Pedro Pérez-Segura, Alberto Ocaña
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 2569-2581 (2023)
Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified in 8–15% of the pa
Externí odkaz:
https://doaj.org/article/e41c2709dfde49eaa725839de2ad6b27
Autor:
Lucía Paniagua-Herranz, Irene Moreno, Cristina Nieto-Jiménez, Esther Garcia-Lorenzo, Cristina Díaz-Tejeiro, Adrián Sanvicente, Bernard Doger, Manuel Pedregal, Jorge Ramón, Jorge Bartolomé, Arancha Manzano, Balázs Gyorffy, Álvaro Gutierrez-Uzquiza, Pedro Pérez Segura, Emiliano Calvo, Víctor Moreno, Alberto Ocana
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2222 (2024)
The identification of surfaceome proteins is a main goal in cancer research to design antibody-based therapeutic strategies. T cell engagers based on KLK2, a kallikrein specifically expressed in prostate cancer (PRAD), are currently in early clinical
Externí odkaz:
https://doaj.org/article/c3b8403f9c0744b0baf28b3578bf3380
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-9 (2022)
Abstract Degradation of targeted proteins using proteolysis targeting chimeras (PROTACs) has gained momentum. A PROTAC is a bifunctional molecule that consists of three parts: a ligand that interacts with the protein to be degraded, another ligand th
Externí odkaz:
https://doaj.org/article/bb12255a4c6143919596c5fcbb92f31e
Autor:
Lucía Paniagua-Herranz, Bernard Doger, Cristina Díaz-Tejeiro, Adrián Sanvicente, Cristina Nieto-Jiménez, Víctor Moreno, Pedro Pérez Segura, Balazs Gyorffy, Emiliano Calvo, Alberto Ocana
Publikováno v:
Cancers, Vol 15, Iss 12, p 3250 (2023)
Background: The identification of proteins in the cellular membrane of the tumoral cell is a key to the design of therapeutic agents. Recently, the bi-specific antibody amivantamab, targeting the oncogenic membrane proteins EGFR and MET, received reg
Externí odkaz:
https://doaj.org/article/1900dd6469094e079bc45ccf5b2f26bf
Autor:
María del Mar Noblejas-López, Cristina Nieto-Jiménez, Eva M. Galán-Moya, David Tebar-García, Juan Carlos Montero, Atanasio Pandiella, Miguel Burgos, Alberto Ocaña
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-12 (2021)
Abstract Background Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to increase its antitumor
Externí odkaz:
https://doaj.org/article/27735656da444e08a86d58977135ef31